Stock

Citius Pharmaceuticals, Inc. CTXR

$0.53-6.70%

All stocks Create account to unlock

Overview

CTXR market data

Price History

CTXR price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for CTXR. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

4 captured

Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August · Jul 21, 2026, 1:19 PM

8-K filing — Citius Pharmaceuticals, Inc. (CTXR) · Jun 1, 2026, 8:30 PM

Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual Meeting · Jun 1, 2026, 11:21 AM

HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4 · May 18, 2026, 3:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock